T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$2.6B |
| 2 |
BNY
Bank of New York Mellon
BNY
|
+$1.1B |
| 3 |
Elevance Health
ELV
|
+$903M |
| 4 |
DD
Du Pont De Nemours E I
DD
|
+$873M |
| 5 |
Medtronic
MDT
|
+$868M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$3.89B |
| 2 |
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
|
+$1.06B |
| 3 |
CFN
CAREFUSION CORPORATION
CFN
|
+$946M |
| 4 |
Aptiv
APTV
|
+$886M |
| 5 |
KSU
Kansas City Southern
KSU
|
+$662M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.05% |
| 2 | Consumer Discretionary | 13.82% |
| 3 | Financials | 13.14% |
| 4 | Industrials | 11.9% |
| 5 | Technology | 9.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1101
Clearway Energy Class C
CWEN
$7.02B
| $21.5M | ﹤0.01% |
846,080
+27,780
| +3% | +$722K |
|
1102
Insteel Industries
IIIN
$634M
| $21.4M | ﹤0.01% |
990,950
+6,050
| +0.6% | +$129K |
|
|
IVAC
1103
DELISTED
Intevac Inc
IVAC
| $21.4M | ﹤0.01% |
3,480,016
-127,014
| -4% | -$861K |
|
1104
Helen of Troy
HELE
$699M
| $21.4M | ﹤0.01% |
262,000
+15,100
| +6% | +$1.15M |
|
1105
CBRE Group
CBRE
$44B
| $21.3M | ﹤0.01% |
551,355
+4,600
| +0.8% | +$159K |
|
|
ADVM
1106
DELISTED
Adverum Biotechnologies
ADVM
| $21.3M | ﹤0.01% |
52,658
-49,887
| -49% | -$21.1M |
|
|
ISIL
1107
DELISTED
Intersil Corp
ISIL
| $21.3M | ﹤0.01% |
1,487,582
+170
| +0% | +$2.52K |
|
1108
Autohome
ATHM
$2.6B
| $21.3M | ﹤0.01% |
484,436
+27,355
| +6% | +$1.07M |
|
1109
Larimar Therapeutics
LRMR
$444M
| $21.1M | ﹤0.01% |
+44,380
| New | +$21.1M |
|
1110
WEC Energy
WEC
$35.9B
| $21.1M | ﹤0.01% |
426,060
+36,480
| +9% | +$1.91M |
|
1111
Oil-Dri
ODC
$1.27B
| $21M | ﹤0.01% |
1,249,030
-2,382
| -0.2% | -$37K |
|
1112
Graphic Packaging
GPK
$3.51B
| $20.9M | ﹤0.01% |
1,437,013
+106,900
| +8% | +$1.56M |
|
1113
TAL Education Group
TAL
$6.43B
| $20.9M | ﹤0.01% |
+3,766,500
| New | +$19.2M |
|
|
PNY
1114
DELISTED
PIEDMONT NATURAL GAS CO INC(NC
PNY
| $20.9M | ﹤0.01% |
564,940
+534,640
| +1,764% | +$20.4M |
|
|
DDC
1115
DELISTED
Dominion Diamond Corporation
DDC
| $20.8M | ﹤0.01% |
1,219,785
+1,145
| +0.1% | +$19.3K |
|
|
WGL
1116
DELISTED
Wgl Holdings
WGL
| $20.8M | ﹤0.01% |
369,125
+348,264
| +1,669% | +$19.1M |
|
1117
Golub Capital BDC
GBDC
$3.48B
| $20.8M | ﹤0.01% |
1,210,191
-66,212
| -5% | -$1.15M |
|
1118
MACOM Technology Solutions
MTSI
$23.5B
| $20.7M | ﹤0.01% |
554,690
-179,080
| -24% | -$5.99M |
|
|
AKRX
1119
DELISTED
Akorn Inc
AKRX
| $20.7M | ﹤0.01% |
434,849
-2,151
| -0.5% | -$97.7K |
|
|
CSLT
1120
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $20.6M | ﹤0.01% |
2,648,423
-719,747
| -21% | -$6.16M |
|
|
LDR
1121
DELISTED
Landauer Inc
LDR
| $20.5M | ﹤0.01% |
584,570
-113,500
| -16% | -$3.83M |
|
|
CUDA
1122
DELISTED
Barracuda Networks, Inc.
CUDA
| $20.5M | ﹤0.01% |
533,080
-12,300
| -2% | -$455K |
|
1123
F5
FFIV
$23.6B
| $20.5M | ﹤0.01% |
178,295
-1,720
| -1% | -$202K |
|
|
CNR
1124
DELISTED
Cornerstone Building Brands, Inc.
CNR
| $20.5M | ﹤0.01% |
1,183,972
-455,160
| -28% | -$7.59M |
|
|
CALA
1125
DELISTED
Calithera Biosciences, Inc
CALA
| $20.4M | ﹤0.01% |
62,063
-1,380
| -2% | -$491K |
|
Similar funds
T. Rowe Price Associates's Q1 2015 Portfolio in Review
As of Q1 2015, T. Rowe Price Associates held 2,630 positions worth $484B, up 2.8% from $471B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
T. Rowe Price Associates's Q1 2015 filing shows 93 new, 1,078 increased, 887 reduced and 93 closed positions. Its largest new stake was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M. The largest sale was Allergan Inc, an estimated $3.89B.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 20% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q1 2015 buy was ACTAVIS PLC Pfd Conv Ser A (Irl): 516,600 shares worth $532M.
- T. Rowe Price Associates added most to Allergan plc in Q1 2015, an estimated $2.6B increase.
- T. Rowe Price Associates's biggest Q1 2015 reduction was Aptiv, cutting an estimated $886M.
- T. Rowe Price Associates fully exited Allergan Inc in Q1 2015, selling an estimated $3.89B.
- T. Rowe Price Associates's ten largest holdings make up 13% of its $484B portfolio in Q1 2015.
- T. Rowe Price Associates opened 93 new positions and closed 93 in Q1 2015.
- T. Rowe Price Associates's portfolio value rose 2.8% quarter-over-quarter to $484B.
Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.